ALDH2 Polymorphism rs671 is A Predictor of Immune Checkpoint Inhibitor Efficacy Against Chest Malignancies

Akiko Matsumoto (matsumoa@cc.saga-u.ac.jp)
Saga University

Chiho Nakashima
Saga University

Shinya Kimura
Saga University

Eizaburo Sueoka
Saga University

Naoko Aragane
Saga University

Research Article

Keywords: ALDH2, rs671, immune checkpoint inhibitors, chest malignancy

DOI: https://doi.org/10.21203/rs.3.rs-257337/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Aldehyde dehydrogenase 2 (ALDH2) plays an important role in the endogenous aldehyde detoxification of various types of cells. ALDH2*2, a variant allele of the ALDH2 polymorphism rs671, leads to decreased enzymatic activity. ALDH2*2 may enhance tumor antigen presentation due to aldehyde-induced DNA damage while suppressing peripheral blood T cell counts and T cell activation.

Methods

On the basis of our hypothesis that rs671 affects the sensitivity of immune checkpoint inhibitors (ICIs), we evaluated the effects of rs671 on patients with chest malignancies who started ICI therapy in 2016–2019. The cohort consisted of 105 cases, including 64 adenocarcinoma and 30 squamous cell carcinoma patients, 49 of whom were ALDH2*2 carriers. Nivolumab, Pembrolizumab, or Atezolizumab was used for the first ICI treatment.

Results

The best response to ICI therapy (partial response/stable disease/progressive disease) was 36%/50%/14% in the rs671(−) cases; however, the response was relatively poor in the rs671(+) cases (27%/29%/45%, respectively) (p = 0.002). The hazard ratio (95% confidence interval) of disease progression within the observation period of 6 months for the rs671(+) cases was estimated to be 5.0 (2.5–10) after the adjustment for covariates, including sex, Brinkman index, treatment line, tumor tissue programmed death-ligand 1 positivity rate, and tumor tissue EGFR mutation. This association was also maintained in a stratified analysis, suggesting that ALDH2*2 is an independent negative predictive factor for the short-term prognosis of ICI therapy. Thus, the progression-free survival (PFS) ratio of the rs671(+) cases decreased rapidly after ICI initiation but was eventually higher than that of the rs671(−) cases (restricted mean survival time in 12 months from 2 to 3 years afterward was 1.3 times that of the rs671(−) cases). Moreover, the highest PFS ratio after 2 years among sub-groups was found in the first-line treatment group of rs671(+) patients (40%).

Conclusions

Our study suggests that rs671 may be an accurate and cost-effective predictor of ICI treatment, in which optimal case selection is an important issue.

1 Background
Aldehyde dehydrogenase 2 (ALDH2) is expressed in many tissues, including blood cells[1, 2], and metabolizes endogenous aldehydes, such as formaldehyde, acetaldehyde, and 4 hydroxynonenal (4HNE) [3, 4]. Approximately half of the Japanese population and at least 2% of the global population shows the low-activity phenotype derived from the ALDH2 genetic polymorphism rs671 (the variant allele is named ALDH2*2), which is associated with differences in lifestyle habits, disease risks, and drug sensitivities[5, 6]. The association is complicated, bidirectional, and rather strong[7]. For example, esophageal cancer is less common among ALDH2*2 carriers due to reduced drinking habits, but ALDH2*2 carriers with drinking habits show the highest risk because of accumulated aldehydes[8]. Additionally, ALDH2*2 is reported to increase the risk for leprosy[9], whereas viral hepatitis is mild in ALDH2*2 carriers[10], likely due to the alleviation of inflammation by the presence of aldehydes[11, 12]. Because hepatitis is a primary carcinogenesis promoter, it is reasonable that ALDH2*2 is reported as a protective factor against liver cancer[13, 14].

Immune checkpoint inhibitors (ICIs) are an innovative cancer treatment that provides benefits for some but not the majority of patients; therefore, understanding the ICI-sensitive population is an important challenge. To date, rs671 has not been studied as a potential predictor of ICI treatment, but it may have a complicated, bidirectional, and strong effect on ICI therapy for the following reasons: 1) Cancer cells of ALDH2*2 carriers may show more DNA damage induced by aldehyde exposure during smoking and drinking[15, 16], resulting in an increased presentation of antigens to immune cells, which is advantageous in ICI treatment. 2) Because endogenous 4HNE, a typical endogenous aldehyde that accumulates in ALDH2*2 carriers, delays cell proliferation[3, 17–20], ICI resistance due to genetic mutations in cancer cells[21, 22] is less likely to occur. 3) However, high aldehyde concentrations can suppress immune cell activation[12], making the short-term effect of ICIs difficult to detect. 4) Nevertheless, T cell exhaustion is unlikely to occur[23, 24], and this may be advantageous in long-term ICI therapy. 5) Lastly, the low T cell count in the peripheral blood of ALDH2*2 carriers reported previously may have a negative effect on ICI treatment[25]. Thus, to verify the hypothesis that ALDH2*2 carriers show a different ICI sensitivity compared with non-carriers, we investigated patients with ICI-treated chest malignancies.

2 Methods

2.1 Patients

The subjects were 106 patients with chest malignancies who received ICI treatment at the Division of Hematology, Respiratory Medicine and Oncology, Saga University School of Medicine from February 2016 to May 2019 and provided written consent for genetic analyses. There was no restriction on the number of ICI doses, type of ICI, and chemotherapy after the first ICI dose. We obtained relevant information from the electronic medical records. The ALDH2 genotype (rs671) was determined in peripheral blood mononuclear DNA stored at −20°C using a TaqMan® SNP genotyping assay system in accordance with the instructions (ThermoFisher Scientific, Waltham, MA, USA). One patient was excluded from the study
after less than 3 months of observation without disease progression. The study was approved by the clinical study ethics review committee of Saga University (project ID R1-16) and conducted accordingly.

2.2 Statistics

2.2.1 Main outcomes: best response to ICI therapy

One of the main outcomes was the best response to ICI treatment. Best responses were classified as Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD) according to RECIST Ver1.1.[26]. CR is defined as the disappearance of all target lesions with any pathological lymph nodes reduced in the short axis to < 10 mm and PR as at least a 30% decrease in the sum of target lesion diameters, taking as reference the baseline sum diameters. PD is defined as at least a 20% increase in the sum of target lesion diameters, taking as reference the smallest sum, and the sum must also demonstrate an absolute increase of at least 5 mm. Lastly, SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters.

2.2.2 Main outcomes: restricted mean survival time (RMST)

The RMST introduced by Royston and Parmar[27] of the progression-free survival (PFS) was used because a proportional hazard assumption has not been established between the rs671 groups for PFS (Figs. 1, S1). RMST was estimated as the area under the survival curve between the time points (LIFETEST procedure in SAS 9.4, SAS Institute Inc., Cary, NC, USA).

2.2.3 Secondary outcomes: PFS ratio during a 6-month observation period

From the biological background described in the Background section, the effect of ICls on short-term prognosis and long-term prognosis may differ for each rs671 group. From the report on the adhesion time of programmed cell death-1 (PD-1) antibodies and memory T cells,[21] the half-life of ICls is estimated to be several months. The longer the observation period, the more effects of time-dependent covariates that cannot be adjusted; for example, the number of ICI administrations after the second dose (up to 68 times in this study) (Table S1), drug used, presence or absence of adverse reactions, and onset time of adverse reactions. Thus, we aimed to directly compare the short-term effects of the initial ICI by limiting the observation period. Because proportional hazard assumption during this period is established (Fig. S1), a Cox proportional hazard model was used to estimate the hazard ratio (HR) after multivariate adjustment (PHREG procedure in SAS 9.4). Covariates were identified as attributes suspected to be associated with disease progression or rs671. For example, EGFR mutations in tumor tissue, female sex, non-smoker, and adenocarcinoma tissues are predictors of poor prognosis,[28–30], and EGFR mutations and programmed death-ligand 1 (PD-L1) expression are associated with smoking habits.[30, 31] Smoking habit is also associated with rs671[32, 33]. Thus, sex, age (continuous), Brinkman index (< 100, < 1000, ≥ 1000) (ordinal), type of first ICI, tumor histotype, TNM classification (categorical), number of lines (first, second, third, and later) (categorical), chemistry with ICls, PD-L1 positivity ratio (< 1%, < 50%, -100%, unassessed)
(categorical), and EGFR mutation ((+), (-), unassessed) (categorical) were set as the covariates. Additionally, as a time-dependent covariate, the presence or absence of immune-related adverse events (irAEs) (defined as ICI withdrawal or prednisolone administration due to immune-related side effects) that occurred prior to disease progression was used. The number of days before the appearance of irAEs was entered as a continuous variable (Supporting information, SAS code). Chemotherapy, which started before disease progression, was also considered. However, because it was applied to only one case, it was not used as a variable. In addition, stratified analyses were performed in case the multivariate adjustment was inadequate.

2.2.4 PFS ratio per rs671 group

The PFS ratio was determined by rs671 groups because the effects of covariates on ICI treatment are likely to differ between rs671 groups based on biological assumptions. For example, chemotherapy before ICI for rs671(+) patients may cause more T cell immunity loss because their basic T cell count is lower than that of rs671(−) patients[25]. If grouped by rs671, the proportional hazard assumption for the total observation period is maintained between sub-groups (Fig. 2). Therefore, the HR was estimated using a Cox proportional hazard model (PHREG procedure in SAS 9.4).

3 Results

3.1 Basic characteristics

The characteristics of the patients are shown in Table 1. The distribution of tumor tissue PD-L1 positivity rates was different between the ALDH2 genotypes. In the time-dependent variables shown in Table S1, the number of ICI administrations was low in the rs671(+) group.
|                                | Total | Rs671(−) | Rs671(+) | P   |
|--------------------------------|-------|----------|----------|-----|
| All                            | 105   | 56       | 49       |     |
| Before ICI                     |       |          |          |     |
| Sex                            |       |          |          |     |
| Male                           | 89    | (85%)    | 44 (79%) | 45  (92%) 0.059 |
| Female                         | 16    | (15%)    | 12 (21%) | 4 (8%) |
| Age (years)                    |       |          |          |     |
| Median (IQR)                   | 69    | 69       | 69       | 0.835 |
| 40–49                          | 6     | (6%)     | 4 (7%)   | 2 (4%) 0.970 |
| 50–59                          | 12    | (11%)    | 6 (11%)  | 6 (12%) |
| 60–69                          | 37    | (35%)    | 20 (36%) | 17 (35%) |
| 70–79                          | 46    | (44%)    | 24 (43%) | 22 (45%) |
| 80–89                          | 4     | (4%)     | 2 (4%)   | 2 (4%) |
| Brinkman Index                 |       |          |          |     |
| < 100                          | 14    | (13%)    | 10 (18%) | 4 (8%) 0.330 |
| < 1000                         | 39    | (37%)    | 19 (34%) | 20 (41%) |
| ≥ 1000                         | 52    | (50%)    | 27 (48%) | 25 (51%) |
| Type of ICI (first dose)       |       |          |          |     |
| Nivolumab                      | 40    | (38%)    | 23 (41%) | 17 (35%) 0.658 |
| Pembrolizumab                  | 45    | (43%)    | 24 (43%) | 21 (43%) |
| Atezolizumab                   | 20    | (19%)    | 9 (16%)  | 11 (22%) |
| Tumor histotype                |       |          |          |     |
| Adenocarcinoma                 | 64    | (61%)    | 31 (55%) | 33 (67%) 0.176 |
| Squamous cell carcinoma        | 30    | (29%)    | 19 (34%) | 11 (22%) |
| Pleomorphic carcinoma          | 5     | (5%)     | 1 (2%)   | 4 (8%) |
| Mesothelioma                   | 2     | (2%)     | 2 (4%)   | 0 (0%) |

Rs671(−); ALDH2*1/*1, Rs671(+) ALDH2*1/*2 or ALDH2*2/*2, ICI; immune checkpoint inhibitor, IQR; interquartile range, PD-L1; programmed death-ligand 1, EGFR, epidermal growth factor receptor.
3.2 ICI best response and RMST

The best response to ICI therapy is shown in Table 2. In all cases, the best effect was observed at the initial ICI evaluation, and the response was better in the rs671(−) group than in the rs671(+) group. The PFS curve (Fig. 1) also suggested that ALDH2*2 has a negative effect early after ICI initiation, but after 2 years, the PFS ratio was higher in the rs671(+) group than in the rs671(−) group, and after 2–3 years (12-month period), the RMST was 0.26 in the rs671(+) group and 0.20 in the rs671(−) group (Table 3).
Table 2
Overall best response per RECIST Ver1.1. by ALDH2 genotype.

| Best response to immune checkpoint inhibitor | Total | Rs671(−) | Rs671(+) | p     |
|---------------------------------------------|-------|----------|----------|-------|
| Complete response                           | 0     | 0        | 0        | 0.0022|
| Partial response                             | 33    | 20       | 13       |       |
| Stable disease                               | 42    | 28       | 14       |       |
| Progressive disease                          | 30    | 8        | 22       |       |
| Disease control rate                         | 71%   | 86%      | 55%      | 0.0005|

p; probability value for Chi-squared test, Fisher's exact test, or Wilcoxon rank-sum test.

Rs671(−); ALDH2*1/*1, rs671(+); ALDH2*1/*2 or ALDH2*2/*2, disease control rate; (all − progressive disease)/all, p; probability value for Chi-squared test.

Table 3
Progression-free survival rate after the initiation of immune checkpoint inhibitors.

| Observation period | Restricted mean survival time |
|--------------------|-------------------------------|
|                    | Rs671(−) | Rs671(+) |
| 0–6 months         | 0.82     | 0.58     |
| 6–12 months        | 0.46     | 0.31     |
| 12–24 months       | 0.25     | 0.26     |
| 24–36 months       | 0.20     | 0.26     |

Rs671(−); ALDH2*1/*1, rs671(+); ALDH2*1/*2 or ALDH2*2/*2.

3.3 Multivariate-adjusted HR during a 6-month observation period

The multivariate-adjusted HR during a 6-month observation period is shown in Table 4. In model 3 with all variables, the HR (95% confidence interval (CI), p-value) of the rs671(+) group was estimated to be 5.0 (2.5–10, p < 0.0001). It was 4.9 (2.4–10, p < 0.0001) (Akaike's Information Criterion = 462) and almost unchanged after the adjustment of the time-dependent variables (the presence or absence of irAEs and timing of onset). In the stratified analysis, the HR was estimated to be high in the rs671(+) group almost consistently (Table 5).
Table 4
Hazard ratio of cancer progression for \textit{ALDH2*2} carriers estimated from a 6-month observation.

| Rs671     | HR        | 95% CI       | p       | AIC |
|-----------|-----------|--------------|---------|-----|
| Model 1   | (-)       | 1.00         | (reference) | 464 |
|           | (+)       | 3.33         | (1.80–6.15) | 0.0001 |
| Model 2   | (-)       | 1.00         | (reference) | 465 |
|           | (+)       | 4.89         | (2.37–10.1) | < 0.0001 |
| Model 3   | (-)       | 1.00         | (reference) | 460 |
|           | (+)       | 5.04         | (2.48–10.2) | < 0.0001 |

Rs671(−); \textit{ALDH2*1/*1}, rs671(+); \textit{ALDH2*1/*2} or \textit{ALDH2*2/*2}, HR; hazard ratio by Cox proportional hazard model, CI; confidence interval, AIC; Akaike’s Information Criterion.

Model 1: adjusted for sex, age (continuous), Brinkman Index (< 100, < 1000, ≥1000) (ordinal), type of first immune checkpoint inhibitor (ICI), tumor histotype, TNM classification (categorical), number of lines (first, second, third, and later) (categorical), and chemotherapy with ICI.

Model 2: adjusted for the covariates in model 1 and the PD-L1 positivity ratio (< 1%, < 50%, -100%, unassessed).

Model 3: adjusted for the covariates in model 2 and \textit{EGFR} mutation ((+), (-), unassessed).
Table 5
Stratified hazard ratio of cancer progression for ALDH2*2 carriers estimated from a 6-month observation.

| Category                                      | HR   | 95% CI   | p       |
|-----------------------------------------------|------|----------|---------|
| **Sex**                                       |      |          |         |
| Male (N = 89)                                 | 8.72 | 3.36–22.6| < 0.0001|
| Female (N = 16)                               | Non-estimable |      |         |
| **Age**                                       |      |          |         |
| < 70 (N = 55)                                 | 2.81 | 0.85–9.27| 0.0892  |
| ≥ 70 (N = 50)                                 | 7.55 | 1.74–32.6| 0.0068  |
| **Brinkman Index**                            |      |          |         |
| < 1000 (N = 53)                               | 5.82 | 1.60–21.1| 0.0074  |
| ≥ 1000 (N = 52)                               | 6.07 | 1.56–23.5| 0.0091  |
| **Type of immune checkpoint inhibitor**        |      |          |         |
| Pembrolizumab (N = 45)                        | 6.02 | 1.46–24.8| 0.0131  |
| Nivolumab and Atezolizumab (N = 60)           | 4.34 | 1.36–13.8| 0.0131  |
| **Tumor histotype**                           |      |          |         |
| Adenocarcinoma (N = 64)                       | 6.77 | 2.43–18.9| 0.0003  |
| Others (N = 41)                               | 3.07 | 0.47–19.9| 0.2394  |
| **TNM classification**                        |      |          |         |
| Stage III (N = 25)                            | Non-estimable |      |         |
| Stage IV (N = 51)                             | 21.3 | 3.62–126 | 0.0007  |
| **Treatment line**                            |      |          |         |
| First-line (N = 41)                           | 3.70 | 0.86–15.9| 0.0783  |
| Second-line and later (N = 64)                | 8.39 | 2.94–24.0| < 0.0001|
| **Chemotherapy with first ICI**               |      |          |         |
| Yes (N = 6)                                   | Non-estimable |      |         |
| No (N = 99)                                   | 4.91 | 2.41–9.99| < 0.0001|
| **PD-L1 (+) ratio in cancer tissue**          |      |          |         |
| < 50% (N = 42)                                | 10.9 | 2.38–49.9| 0.0021  |
| HR | 95% CI | p   |
|----|--------|-----|
| $\geq 50\%$ (N = 48) | 4.01 | 1.31–12.3 | 0.0152 |
| EGFR mutation in cancer tissue | | | |
| (+) (N = 8) | Non-estimable | | |
| (-) (N = 81) | 14.1 | 4.30–46.5 | < 0.0001 |

Reference = ALDH2*1/*1 carriers. HR; hazard ratio by Cox proportional hazard model adjusted for covariates used in Model 3 in Table 2. CI; confidence interval, PD-L1; programmed death-ligand 1, EGFR; epidermal growth factor receptor. Cases with unknown TNM classification (N = 29), unknown PD-L1 (+) ratio in cancer tissue (N = 15), and unknown EGFR mutation in cancer tissue (N = 16) were excluded.

3.4 Association between PFS and the other variables by rs671 groups

The PFS curve is shown in Fig. 2, and the multivariate-adjusted HR is shown in Table 6. The multivariate-adjusted HR of PFS showed significant differences by sex, type of ICI, treatment line, PD-L1 antibody positivity rate, and EGFR mutation for either type of rs671; an association with rs671 was suggested for treatment line, PD-L1 antibody positivity rate, and EGFR mutation based on the interaction analysis. The treatment line was associated with PFS only in the rs671(+) group, and the first-line group showed the best treatment outcome. The PD-L1 positivity rate was also associated with PFS only in the rs671(+) group; however, there was no dose-response relationship (a middle level was associated with the highest HR). Only the rs671(−) group showed short PFS among the groups with EGFR mutations.
Table 6
Hazard ratio of cancer progression by *ALDH2* genotype estimated from the entire observation period.

| Explanatory variables | Rs671(−) (N = 56) |  | Rs671(+) (N = 49) |  | p for interaction |
|-----------------------|--------------------|---|--------------------|---|------------------|
|                       | HR  | 95% CI | p  | HR  | 95% CI | p  |
| Sex (reference = male) |     |        |    |     |        |    |
| Female                | 5.07| 1.22   | 21.1| 0.0255 | 0.87   | 0.16 | 4.59 | 0.8662 | 0.0785 |
| Age                   |     |        |    |     |        |    |
| Per one year          | 0.99| 0.93   | 1.06| 0.7345 | 1.04   | 0.98 | 1.11 | 0.2365 |
| Brinkman Index (< 100, < 1000, ≥ 1000) (ordinal) |     |        |    |     |        |    |
| Per category          | 1.64| 0.70   | 3.81| 0.2539 | 1.45   | 0.67 | 3.17 | 0.346  |
| Type of ICI (reference = pembrolizumab) |     |        |    |     |        |    |
| Atezolizumab          | 0.93| 0.10   | 8.93| 0.9476 | 0.84   | 0.15 | 4.71 | 0.8403 | 0.8472 |
| Nivolumab             | 1.02| 0.15   | 6.84| 0.9877 | 0.07   | 0.01 | 0.50 | 0.0078 | 0.0521 |
| Tumor histotype (reference = Squamous cell carcinoma) |     |        |    |     |        |    |
| Adenocarcinoma        | 0.78| 0.10   | 6.33| 0.8167 | 1.93   | 0.56 | 6.60 | 0.2955 |
| Pleomorphic carcinoma | 0.00| 0.00   | NE | 0.9932 | 0.92   | 0.10 | 8.86 | 0.9417 |
| Mesothelioma          | 2.35| 0.11   | 48.8| 0.5817 | —     |      |      |        |
| Other                 | 1.05| 0.07   | 17.0| 0.9742 | 1.45   | 0.06 | 37.3 | 0.824  |
| TNM classification (reference = stage III) |     |        |    |     |        |    |
| Stage IV              | 1.57| 0.22   | 11.4| 0.6546 | 0.50   | 0.13 | 1.98 | 0.3233 |
| Unknown               | 1.68| 0.30   | 9.30| 0.5527 | 1.33   | 0.35 | 5.04 | 0.6753 |
| Treatment line (reference = third-line and later) |     |        |    |     |        |    |
| First-line            | 4.03| 0.45   | 36.4| 0.2147 | 0.07   | 0.01 | 0.53 | 0.0098 | 0.0049 |
| Explanatory variables | Rs671(−) (N = 56) | Rs671(+) (N = 49) | p for interaction |
|-----------------------|-------------------|-------------------|------------------|
|                       | HR                | 95% CI | p | HR | 95% CI | p |       |
| Second-line           | 2.69              | 0.32   | 22.9 | 0.3640 | 0.56 | 0.13 | 2.43 | 0.4336 | 0.1810 |
| Chemotherapy with first ICI (reference = no) | | | | | | | | |
| Yes                   | 3.94              | 0.30   | 51.8 | 0.2964 | > 999 | 0.00 | NE | 0.9877 |
| PD-L1 (+) ratio in cancer tissue (reference = < 1%) | | | | | | | | |
| 50%                   | 0.46              | 0.06   | 3.83 | 0.4753 | 27.0 | 4.64 | 158 | 0.0002 | 0.0116 |
| -100%                 | 0.49              | 0.06   | 3.71 | 0.4879 | 1.99 | 0.27 | 14.4 | 0.4969 | 0.2838 |
| Unassessed            | 1.21              | 0.15   | 9.44 | 0.8589 | 176 | 12.9 | > 999 | 0.0001 | 0.0079 |
| EGFR mutation in cancer tissue (reference = (-)) | | | | | | | | |
| (+)                   | 28.4              | 2.36   | 342 | 0.0084 | 0.32 | 0.03 | 2.95 | 0.3127 | 0.0041 |
| Unassessed            | 1.65              | 0.20   | 13.4 | 0.6401 | 0.23 | 0.03 | 2.20 | 0.2033 | 0.0602 |

Rs671(−); $ALDH2^{*1/*1}$, rs671(+); $ALDH2^{*1/*2}$ or $ALDH2^{*2/*2}$, HR; hazard ratio by the Cox proportional hazard model includes all explanatory covariates shown above, CI; confidence interval, ICI; immune checkpoint inhibitor, NE; non-estimable, PD-L1; programmed death-ligand 1, $EGFR$; epidermal growth factor receptor. The p-value for interactions was estimated by the Cox proportional hazard model including all explanatory covariates shown above, rs671, and interaction in terms of sex*rs671, type of ICI*rs671, treatment line*rs671, PD-L1 ratio*rs671, and $EGFR$ mutation*rs671.

### 4 Discussion

As expected, the $ALDH2$ polymorphism rs671 influenced the effects of ICI therapy on chest malignancies. $ALDH2^{*2}$ had a negative effect on short-term prognosis, although it was unlikely to affect long-term prognosis. According to multivariable and stratified analyses, the negative effect was independent of sex, smoking habit, PD-L1 expression rate, and $EGFR$ mutation. Compared with $EGFR$ mutation, which has been shown to be associated with poor prognosis independent of ICI or initial ICI efficacy[30, 34], rs671 may be more strongly associated with initial ICI efficacy. However, $ALDH2^{*2}$ showed no negative effect on long-term survivors, especially the first treatment line group; thus, we found that $ALDH2^{*2}$ is not consistently associated with negative effects.
Several findings that support the negative impact of *ALDH2* on the short-term prognosis of ICI therapy have been reported. Gao et al. (2018) showed that drug-induced T-cell hepatitis is suppressed by exogenous acetaldehyde. Mechanistically, aldehyde suppresses the secretion of cytokines by inhibiting the phosphatidylinositol 3-kinase (PI3K)-Akt pathway in T cells or promotes the secretion of glucocorticoids that suppress the activation of T cells[12]. This suppression of the PI3K-Akt pathway has also been confirmed in the cardiomyocytes of *Aldh2−/−* mice, in which endogenous aldehydes accumulate in the absence of exogenous aldehyde[35]. These findings suggest that endogenous aldehyde also suppresses the PI3K-Akt pathway in T cells. The PI3K-Akt pathway is important for T cell differentiation[36] and has been shown to decrease the number of T cells in the thymus gland when activity is impaired[37, 38]. In fact, we found that the number of T cells in the peripheral blood of *Aldh2−/−* mice and *ALDH2* carriers is low[25]. On the basis of these findings, we hypothesize that *ALDH2* negatively affects the initial ICI efficacy via suppression of the PI3K-Akt pathway in T cells due to endogenous aldehyde accumulation.

However, as explained above, endogenous aldehyde can also be advantageous. In the present study, the PFS ratio in the rs671(+) group decreased rapidly but was eventually higher than that of the rs671(−) group (0.21 vs. 0.27). For the first-line group, the PFS ratio after 2 years was 0.37 in the rs671(−) group and 0.40 in the rs671(+) group and was substantially higher compared with that in the other groups (the PFS ratio after 2 years was 0.18–0.23 in the rs671(−) and rs671(+) groups after the second-line treatment). This finding suggests that preventing a decrease in the number of T cells caused by pre-ICI treatment may increase the chances of obtaining a good ICI effect, especially in rs671(+) patients because *ALDH2* carriers have lower T cell counts[25].

The response rate of patients to ICIs is currently insufficient. For example, only 10%–20% of non-small-cell lung cancer (NSCLC)[39, 40] patients respond to this therapy. Therefore, optimal case selection is important. The effects of ICI are affected by the immunity of the host, the intestinal bacterial environment of the host, and tumor tissue factors[41, 42]. The PD-L1 expression level and *EGFR* mutation rate, which are tumor tissue factors, are currently used as predictors in clinical settings. In the present study, there was no association between the PFS and PD-L1 ratio. However, *EGFR* mutation was shown to be a negative predictor for rs671(−), as previously reported. It also has been shown that tissue infiltrating lymphocytes and tumor mutation burden can be predictors of treatment effects, although they have not been applied clinically[42-44]. The most significant limitation of these factors is that highly invasive biopsies are required. Because the microenvironment and gene mutations of tumor cells are known to fluctuate dynamically, collecting tumor tissues immediately before treatment is ideal. However, this may often be difficult due to the condition of patients and the site of lesions. Meanwhile, Hatae et al. (2020) recently showed that blood metabolites reflecting the state of intestinal bacteria and tumor-specific T cell rates are good predictors of ICI effects on NSCLC, although there are still difficulties owing to the number of tested parameters after the start of treatment[45]. Ohue et al. (2019) demonstrated that the effects of ICIs on NSCLC could be predicted by tumor antigens in blood samples collected prior to ICI initiation [HR (95% CI) of PFS in antigen-positive patients is 0.4 (0.2 to 0.9)] [46], and its clinical application is expected.
Compared with these predictors, the analysis of \textit{ALDH2} polymorphisms has some advantages: non-invasive, inexpensive, 100\% determinable, and polymorphisms do not change throughout life.

The limitations of the present study are as follows: 1) The sample size was insufficient to establish prognostic factors specific to rs671(+) patients. 2) Because the present study was limited to Japanese patients with chest malignancies who were mostly men, it cannot be generalized to other types of cancers and populations. 3) Because several time-dependent covariates can affect the outcome, such as adverse reactions and types and doses of second and subsequent ICIs, controlling covariates is insufficient for long-term observation. 4) The biological mechanism is not well supported.

\textbf{Conclusion}

The variant allele of the \textit{ALDH2} polymorphism rs671 was found to be a negative predictor in the early stage of ICI treatment. However, the long-term survivor rate was the highest in the sub-group of patients with the variant allele who received an ICI as first-line treatment. The rs671 polymorphism test is expected to be a cost-effective predictor of ICI efficacy for clinical application. We need to present better personalized strategies by accumulating evidence with a larger sample size and examining the mechanism underlying the findings.

\textbf{List Of Abbreviations}

\begin{itemize}
\item Aldehyde dehydrogenase 2 (ALDH2)
\item Immune checkpoint inhibitors (ICIs)
\item Programmed cell death-1 (PD-1)
\item Programmed death-ligand 1 (PD-L1)
\item Progression-free survival (PFS)
\item 4 hydroxynonenal (4HNE)
\item Complete Response (CR)
\item Partial Response (PR)
\item Stable Disease (SD)
\item Progressive Disease (PD)
\item Restricted mean survival time (RMST)
\item Hazard ratio (HR)
\end{itemize}
Immune-related adverse events (irAEs)

Phosphatidylinositol 3-kinase (PI3K)

Non-small-cell lung cancer (NSCLC)

Declarations

Ethics approval and consent to participate: Informed written consent was obtained from all participants for the study, including genetic analyses and publication. The study was approved by the clinical study ethics review committee of Saga University (project ID R1-16) and conducted accordingly. All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication: Not applicable.

Availability of data and materials: The datasets generated and/or analyzed during the current study are not publicly available due to a potential infringement of privacy but are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.

Funding: This work was supported by JSPS KAKENHI (17K07197).

Authors’ contributions: CN and NA built the database. AM and CN were the major contributors to the analysis and interpretation of the database. AM wrote the manuscript while organizing discussion from CN, SK, ES and NA. CN, SK, ES and NA read and approved the final manuscript.

Acknowledgements: We thank Melissa Crawford, PhD, from Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript.

References

1. Matsumoto A: [Fundamental Properties of Aldehyde Dehydrogenase 2 (ALDH2) and the Importance of the ALDH2 Polymorphism]. Nihon eiseigaku zasshi Japanese journal of hygiene 2016, 71(1):55–68.

2. Gene expression for ALDH2 [https://gtexportal.org/home/gene/ALDH2]

3. Garaycoechea JI, Crossan GP, Langevin F, Daly M, Arends MJ, Patel KJ: Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 2012, 489(7417):571–575.

4. Nakamura J, Holley DW, Kawamoto T, Bultman SJ: The failure of two major formaldehyde catabolism enzymes (ADH5 and ALDH2) leads to partial synthetic lethality in C57BL/6 mice. Genes Environ 2020, 42:21.
5. Matsumoto A: [Importance of an Aldehyde Dehydrogenase 2 Polymorphism in Preventive Medicine]. Nihon eiseigaku zasshi Japanese journal of hygiene 2018, 73(1):9–20.

6. Matsumoto A, Thompson DC, Chen Y, Kitagawa K, Vasiliou V: Roles of defective ALDH2 polymorphism on liver protection and cancer development. Environmental health and preventive medicine 2016, 21(6):395–402.

7. Matsumoto A: The Bidirectional Effect of Defective ALDH2 Polymorphism and Disease Prevention. Adv Exp Med Biol 2019, 1193:69–87.

8. Koyanagi YN, Suzuki E, Imoto I, Kasugai Y, Oze I, Ugai T, Iwase M, Usui Y, Kawakatsu Y, Sawabe M et al: Across-site differences in the mechanism of alcohol-induced digestive tract carcinogenesis: an evaluation by mediation analysis. Cancer research 2020.

9. Wang Z, Mi Z, Wang H, Sun L, Yu G, Fu X, Wang C, Bao F, Yue Z, Zhao Q et al: Discovery of 4 exonic and 1 intergenic novel susceptibility loci for leprosy. Clinical genetics 2018.

10. Yang X, Takeshita T, Hirata M, Sato S, Morimoto K: Effects of alcohol intake and low Km aldehyde dehydrogenase on hepatic function in a high hepatitis C virus-prevalent Japanese island population. Alcoholism, clinical and experimental research 1999, 23(4):751–756.

11. Ganesan M, Krutik VM, Makarov E, Mathews S, Kharbanda KK, Poluektova LY, Casey CA, Osna NA: Acetaldehyde suppresses the display of HBV-MHC class I complexes on HBV-expressing hepatocytes. American journal of physiology 2019, 317(2):G127-G140.

12. Gao Y, Zhou Z, Ren T, Kim SJ, He Y, Seo W, Guillot A, Ding Y, Wu R, Shao S et al: Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoids. Gut 2018.

13. Chien J, Liu J, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Yang HI, Chen CJ: Risk and Predictors of Hepatocellular Carcinoma for Chronic Hepatitis B Patients With Newly Developed Cirrhosis. Journal of gastroenterology and hepatology 2016.

14. Ye X, Wang X, Shang L, Zhu G, Su H, Han C, Qin W, Li G, Peng T: Genetic variants of ALDH2-rs671 and CYP2E1-rs2031920 contributed to risk of hepatocellular carcinoma susceptibility in a Chinese population. Cancer Manag Res 2018, 10:1037–1050.

15. Matsuda T, Kawanishi M, Yagi T, Matsui S, Takebe H: Specific tandem GG to TT base substitutions induced by acetaldehyde are due to intra-strand crosslinks between adjacent guanine bases. Nucleic Acids Res 1998, 26(7):1769–1774.

16. Dingler FA, Wang M, Mu A, Millington CL, Oberbeck N, Watcham S, Pontel LB, Kamimae-Lanning AN, Langevin F, Nadler C et al: Two Aldehyde Clearance Systems Are Essential to Prevent Lethal Formaldehyde Accumulation in Mice and Humans. Molecular cell 2020.

17. Hoshi H, Hao W, Fujita Y, Funayama A, Miyauchi Y, Hashimoto K, Miyamoto K, Iwasaki R, Sato Y, Kobayashi T et al: Aldehyde-stress resulting from Aldh2 mutation promotes osteoporosis due to impaired osteoblastogenesis. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 2012.
18. Endo J, Sano M, Katayama T, Hishiki T, Shinmura K, Morizane S, Matsuhashi T, Katsumata Y, Zhang Y, Ito H et al: Metabolic remodeling induced by mitochondrial aldehyde stress stimulates tolerance to oxidative stress in the heart. Circ Res 2009, 105(11):1118–1127.

19. D’Souza Y, Elharram A, Soon-Shiong R, Andrew RD, Bennett BM: Characterization of Aldh2 mice as an age-related model of cognitive impairment and Alzheimer's disease. Molecular brain 2015, 8(1):27.

20. Kuroda A, Hegab AE, Jingtao G, Yamashita S, Hizawa N, Sakamoto T, Yamada H, Suzuki S, Ishii M, Namkoong H et al: Effects of the common polymorphism in the human aldehyde dehydrogenase 2 (ALDH2) gene on the lung. Respiratory research 2017, 18(1):69.

21. Schoenfeld AJ, Hellmann MD: Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell 2020, 37(4):443–455.

22. Zhao X, Wangmo D, Robertson M, Subramanian S: Acquired Resistance to Immune Checkpoint Blockade Therapies. Cancers (Basel) 2020, 12(5).

23. Buchbinder EI, Desai A: CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol 2016, 39(1):98–106.

24. Wherry EJ: T cell exhaustion. Nat Immunol 2011, 12(6):492–499.

25. Matsumoto A, Terashima Y, Toda E, Akao C, Miyake Y, Matsuo K, Shimano C, Nishida Y, Hara M, Tanaka K et al: Reduced T cell immunity in variant ALDH2 allele carriers. In: The 91th annual meeting of the Japanese Society for Hygiene: 2020; Toyama, Japan; 2020.

26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228–247.

27. Royston P, Parmar MK: Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 2013, 13:152.

28. Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Ren P, Liu D, Li W: Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer Med 2019, 8(8):4023–4031.

29. Peters S, Gettinger S, Johnson ML, Janne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E et al: Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017, 35(24):2781–2789.

30. Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, Wang CL, Chen CY, Yen SH, Tsai CM et al: EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget 2017, 8(58):98384–98393.

31. Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR et al: Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol 2015, 10(12):1726–1735.
32. Masaoka H, Ito H, Gallus S, Watanabe M, Yokomizo A, Eto M, Matsuo K: Combination of ALDH2 and ADH1B polymorphisms is associated with smoking initiation: A large-scale cross-sectional study in a Japanese population. Drug and alcohol dependence 2017, 173:85–91.

33. Masaoka H, Gallus S, Ito H, Watanabe M, Yokomizo A, Eto M, Matsuo K: Aldehyde Dehydrogenase 2 Polymorphism Is a Predictor of Smoking Cessation. Nicotine Tob Res 2017, 19(9):1087–1094.

34. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR et al: EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res 2016, 22(18):4585–4593.

35. Xia G, Fan F, Liu M, Wang S, Wu J, Shen C, Han S, Wang C, Jia J, Zou Y et al: Aldehyde dehydrogenase 2 deficiency blunts compensatory cardiac hypertrophy through modulating Akt phosphorylation early after transverse aorta constriction in mice. Biochim Biophys Acta 2016, 1862(9):1587–1593.

36. Juntilla MM, Koretzky GA: Critical roles of the PI3K/Akt signaling pathway in T cell development. Immunol Lett 2008, 116(2):104–110.

37. Juntilla MM, Wofford JA, Birnbaum MJ, Rathmell JC, Koretzky GA: Akt1 and Akt2 are required for alphabeta thymocyte survival and differentiation. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(29):12105–12110.

38. Webb LM, Vigorito E, Wymann MP, Hirsch E, Turner M: Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 2005, 175(5):2783–2787.

39. Bardhan K, Anagnostou T, Boussiotis VA: The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol 2016, 7:550.

40. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016, 387(10027):1540–1550.

41. Mitsuhashi A, Okuma Y: Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. Clin Transl Oncol 2018, 20(8):966–974.

42. Topalian SL, Taube JM, Anders RA, Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016, 16(5):275–287.

43. Nishino M, Ramaiya NH, Hatabu H, Hodi FS: Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol 2017, 14(11):655–668.

44. Tray N, Weber JS, Adams S: Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application. Cancer Immunol Res 2018, 6(10):1122–1128.

45. Hatae R, Chamoto K, Kim YH, Sonomura K, Taneishi K, Kawaguchi S, Yoshida H, Ozasa H, Sakamori Y, Akrami M et al: Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. JCI Insight 2020, 5(2).
46. Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J, Irei I, Masuda T, Fukuda M, Kinoshita A et al: Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. J Thorac Oncol 2019, 14(12):2071–2083.